Upon analysis of the differential STAT3/5A expression-based survival rates, high expression of both STAT3 and STAT5A was found to be strongly associated with the poorest OS time; and may relate to the enhanced tumorigenicity and lethality of GBM in oncology clinics. The gene discussed is STAT3; the disease is glioblastoma.